CVC Catalyst agreed to acquire a majority stake in WillowWood, the prosthetics maker known for its gel liner technology. The deal places the private‑equity firm alongside existing investors Blue Sea Capital, the Arbogast family and company management. By securing control of a firm that supplies liners, feet and knees, CVC targets a growing niche in medical devices and will leverage its global network to expand sales.

WillowWood pioneered the gel liner, a critical interface that reduces skin irritation and improves gait for amputees. Its product line has expanded into microprocessor‑controlled knees and energy‑return feet, positioning it as a comprehensive provider. The infusion of capital from CVC’s mid‑market strategy is expected to accelerate R&D and broaden distribution in the U.S. and Europe and strengthen partnerships with major healthcare providers.

The transaction, though undisclosed, reflects rising private‑equity interest in orthotics and prosthetics as aging populations drive demand. Existing shareholders retain minority stakes, ensuring continuity of leadership. With CVC now the controlling partner, WillowWood is positioned to scale production and capture a larger share of the $8 billion global prosthetics market. The firm plans to invest in advanced composites for lighter sockets.